XOMA Royalty (XOMA) Competitors $32.43 -0.27 (-0.83%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, INVA, DVAX, MNKD, OPK, GERN, RIGL, ZBIO, MYGN, and VSTMShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), and Verastem (VSTM). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA Innoviva Dynavax Technologies MannKind OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma Myriad Genetics Verastem XOMA (NASDAQ:XOMAO) and XOMA Royalty (NASDAQ:XOMA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Do analysts rate XOMAO or XOMA? XOMA Royalty has a consensus price target of $69.50, indicating a potential upside of 114.33%. Given XOMA Royalty's stronger consensus rating and higher possible upside, analysts clearly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00XOMA Royalty 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals believe in XOMAO or XOMA? 95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, XOMAO or XOMA? XOMA has higher earnings, but lower revenue than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$12.77MN/AN/AN/AN/AXOMA Royalty$28.49M13.76-$13.82M-$1.55-20.92 Does the media refer more to XOMAO or XOMA? In the previous week, XOMA Royalty had 6 more articles in the media than XOMA. MarketBeat recorded 7 mentions for XOMA Royalty and 1 mentions for XOMA. XOMA's average media sentiment score of 1.16 beat XOMA Royalty's score of 0.92 indicating that XOMA is being referred to more favorably in the media. Company Overall Sentiment XOMA Positive XOMA Royalty Positive Is XOMAO or XOMA more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMAN/A N/A N/A XOMA Royalty -27.57%2.63%0.97% SummaryXOMA Royalty beats XOMA on 9 of the 11 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$392.56M$3.08B$5.75B$9.76BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-20.9521.1931.3126.52Price / Sales13.76355.27439.11154.97Price / CashN/A44.6737.7359.36Price / Book5.418.0810.536.64Net Income-$13.82M-$54.08M$3.27B$265.47M7 Day Performance-5.18%-0.67%1.35%0.50%1 Month Performance22.50%5.87%6.13%2.47%1 Year Performance9.92%9.75%49.95%22.11% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.1409 of 5 stars$32.43-0.8%$69.50+114.3%+12.8%$392.56M$28.49M-20.9510XOMAOXOMAN/A$25.46+0.0%N/A-0.1%$0.00$12.77M0.0010INVAInnoviva4.4878 of 5 stars$20.78-0.7%$42.75+105.7%+4.5%$1.32B$358.71M67.03100Positive NewsDVAXDynavax Technologies4.6298 of 5 stars$10.76-0.3%$24.33+126.1%-6.7%$1.27B$277.25M-23.39350MNKDMannKind3.4198 of 5 stars$3.81+2.1%$9.71+155.0%-23.9%$1.14B$285.50M34.64400Analyst ForecastGap DownOPKOPKO Health4.4285 of 5 stars$1.40+2.2%$2.75+96.4%-13.9%$1.09B$664.03M-5.602,997News CoveragePositive NewsGERNGeron3.1064 of 5 stars$1.44-0.7%$4.19+190.8%-68.3%$925.12M$76.99M-11.08229Gap UpRIGLRigel Pharmaceuticals1.6218 of 5 stars$40.07+1.4%$38.20-4.7%+204.7%$708.70M$179.28M7.41160ZBIOZenas BioPharma1.5463 of 5 stars$17.28+2.7%$36.67+112.2%N/A$708.29M$5M-4.87N/AHigh Trading VolumeMYGNMyriad Genetics3.8204 of 5 stars$5.71flat$12.45+118.1%-77.7%$531.28M$837.60M-1.332,700VSTMVerastem3.1344 of 5 stars$7.97-3.0%$13.29+66.7%+279.8%$505.90M$10K-2.4350Gap Down Related Companies and Tools Related Companies XOMA Alternatives Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Geron Alternatives Rigel Pharmaceuticals Alternatives Zenas BioPharma Alternatives Myriad Genetics Alternatives Verastem Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access